Novartis has received regulatory approval from Swissmedic for Coartem Baby, the first malaria treatment specifically designed for newborns and young children. This approval marks a milestone in the global fight against malaria, a disease that caused approximately 597,000 deaths worldwide in 2023, with most fatalities occurring in children under five years old, primarily in Africa. Coartem Baby is a lower-dose formulation of a previously approved antimalarial tablet, combining two active ingredients, artemether and lumefantrine. The medication is cherry-flavored and dissolvable, allowing it to be mixed with milk or breast milk to facilitate administration to infants. The treatment is expected to be rolled out in several African countries, including Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda, within weeks. Health experts view this development as a breakthrough that could help reduce healthcare access inequalities and save thousands of young lives affected by malaria.